NCT06719180 Vaginal Cuff Anesthesia and Post-Operative Pain Medication Use
| NCT ID | NCT06719180 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | MediSys Health Network |
| Condition | Hysterectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2025-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 100 participants in total. It began in 2024-12-01 with a primary completion date of 2025-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine whether an injection of a local anesthetic (Bupivacaine with epinephrine) in the vaginal cuff prior to closure would result in less immediate postoperative pain medication and increase patient comfort/satisfaction.
Eligibility Criteria
Inclusion Criteria: * Patients 18 years and older requiring total laparoscopic hysterectomy with or without bilateral salpingo-oophorectomy for benign conditions * Presence of malignancy Exclusion Criteria: * Conversion to laparotomy * Previous multiple abdominal and/or pelvic surgeries * Significant medical comorbidities or cardiac history * Poor initial Aldrete score4 (\<10) * Significant pre-op pain medication use * Contraindication to any medication that would be used in the study (Bupivacaine, epinephrine, tramadol or oxycodone)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06719180 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Hysterectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06719180 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06719180 currently recruiting?
Yes, NCT06719180 is actively recruiting participants. Contact the research team at hhanna@jhmc.org for enrollment information.
Where is the NCT06719180 trial being conducted?
This trial is being conducted at Flushing, United States.
Who is sponsoring the NCT06719180 clinical trial?
NCT06719180 is sponsored by MediSys Health Network. The trial plans to enroll 100 participants.